Vericel (VCEL) Liabilities and Shareholders Equity (2010 - 2026)

Vericel (VCEL) posted Liabilities and Shareholders Equity of $502.9 million for Q2 2026, up 3.55% sequentially from $485.6 million in Q1 2026, and up 15.44% YoY from $435.6 million in Q2 2025.

Vericel (VCEL) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Vericel has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $502.9 million in Q2 2026.

  • Quarterly Liabilities and Shareholders Equity rose 15.44% year-over-year to $502.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 billion (up 14.64% YoY) and the FY2025 annual result came in at $488.0 million, up 12.77% from the prior year.
  • Liabilities and Shareholders Equity rose to $502.9 million in Q2 2026 per VCEL's latest filing, from $485.6 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $502.9 million in Q2 2026 and troughed at $240.3 million in Q1 2022.
  • A 5-year average of $366.7 million and a median of $366.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity increased 10.3% in 2022, then soared 34.54% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $273.0 million in 2022, then gained by 29.54% to $353.7 million in 2023, then advanced by 22.36% to $432.7 million in 2024, then climbed by 12.77% to $488.0 million in 2025, then rose by 3.05% to $502.9 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $502.9 million, $485.6 million, and $488.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 Vericel 2.26 Bn 2.10 Bn 56.40 Mn 502.87 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 502.87 Mn
Mar 31, 2026 485.63 Mn
Dec 31, 2025 487.97 Mn
Sep 30, 2025 453.27 Mn
Jun 30, 2025 435.61 Mn
Mar 31, 2025 424.59 Mn
Dec 31, 2024 432.72 Mn
Sep 30, 2024 390.41 Mn
Jun 30, 2024 376.84 Mn
Mar 31, 2024 356.66 Mn
Dec 31, 2023 353.66 Mn
Sep 30, 2023 318.13 Mn
Jun 30, 2023 310.71 Mn
Mar 31, 2023 265.10 Mn
Dec 31, 2022 273.00 Mn
Sep 30, 2022 248.02 Mn
Jun 30, 2022 244.82 Mn
Mar 31, 2022 240.29 Mn
Dec 31, 2021 243.71 Mn
Sep 30, 2021 224.14 Mn